National Blood Centre, Italian National Institute of Health, Rome, Italy.
Blood Transfus. 2024 Sep;22(5):429-440. doi: 10.2450/BloodTransfus.730. Epub 2024 Feb 21.
Platelet-rich plasma (PRP) as a non-surgical therapy for facial rejuvenation is increasingly adopted. This article aims to review the literature and critically appraise the available evidence regarding the efficacy and safety of PRP for facial rejuvenation.
An overview of systematic reviews (SRs) of PRP use for facial rejuvenation. The methodological quality of the SRs was assessed using the AMSTAR-2 checklist; quality of the evidence from the trials included in each SR was appraised following the GRADE approach.
Thirteen SRs published between 2015 and 2023, reporting data from 114 overlapping reports, based on 28 individual primary studies (18 uncontrolled reports), were included in this umbrella review. Eight primary studies evaluated PRP in combination with other treatments (laser therapy, fat grafting, hyaluronic acid, basic fibroblast growth factor), and 20 PRP monotherapy. Most of the included primary studies were uncontrolled, and meta-analysis for outcomes related to facial rejuvenation was conducted in only 1 of the 13 SRs, showing that patients treated with PRP as an adjunct treatment have increased satisfaction over controls without PRP (mean difference, 0.63; 95% confidence intervals (CIs) 0.25/1; p=0-001; low certainty of evidence due to risk of bias (ROB) and inconsistency). No other quantitative data were available from the SRs, although 4 SRs concluded in a descriptive way reveal that PRP combined with laser therapy increased subject satisfaction and skin elasticity, and decreased the erythema index (very low certainty of evidence due to imprecision, unsystematic clinical observations, and ROB). The occurrence of adverse events was a predefined outcome in only 2 SRs (15%). Almost all the SRs demonstrated poor compliance with the AMSTAR 2 items, and the confidence in the results of SRs was graded as low or critically low in 12 of the 13 SRs.
The available evidence is insufficient to suggest firm conclusions about the use of PRP, alone or in combination with other treatments, in promoting facial rejuvenation.
富含血小板的血浆(PRP)作为一种非手术疗法,越来越多地用于面部年轻化。本文旨在综述文献,批判性地评估 PRP 用于面部年轻化的疗效和安全性的现有证据。
对 PRP 用于面部年轻化的系统评价(SR)进行概述。使用 AMSTAR-2 清单评估 SR 的方法学质量;使用 GRADE 方法评估每项 SR 中纳入试验的证据质量。
这项伞式综述纳入了 13 项发表于 2015 年至 2023 年的 SR,这些 SR 基于 28 项单独的初步研究(18 项非对照报告),共报道了 114 个重叠报告的数据。8 项初步研究评估了 PRP 与其他治疗方法(激光治疗、脂肪移植、透明质酸、碱性成纤维细胞生长因子)的联合应用,20 项 PRP 单独治疗。纳入的初步研究大多为非对照研究,仅有 1 项 SR 对与面部年轻化相关的结局进行了荟萃分析,结果显示,接受 PRP 辅助治疗的患者满意度高于未接受 PRP 治疗的患者(平均差异,0.63;95%置信区间(CI)0.25/1;p=0-001;证据确定性低,因存在偏倚风险(ROB)和不一致性)。虽然 4 项 SR 以描述性的方式得出结论,表明 PRP 联合激光治疗可提高患者满意度和皮肤弹性,并降低红斑指数(证据确定性极低,因不精确、非系统性临床观察和 ROB),但 SR 中没有其他定量数据。只有 2 项 SR 将不良事件的发生作为一个预设结局(15%)。几乎所有的 SR 都没有很好地遵守 AMSTAR 2 项目,在 13 项 SR 中有 12 项的 SR 结果的可信度被评为低或极低。
目前的证据不足以得出关于 PRP 单独使用或与其他治疗方法联合使用促进面部年轻化的可靠结论。